ALK B ALK-abello A/S Class B

Release date of six-month interim report (Q2) 2018 and audio cast

Release date of six-month interim report (Q2) 2018 and audio cast

                

On Wednesday, 15 August 2018, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its interim report for the six months ended 30 June 2018.

ALK will host a meeting for analysts and institutional investors that day at 1.30 p.m. (CEST) at which Management will review the financial results, the outlook and answer questions.

The meeting will be audio cast live on our website , where the related presentation will be available shortly before the meeting begins.

Participants in the conference call are kindly requested to call in before 1.25 p.m. (CEST).

Danish participants should call in on tel. and international participants should call in on tel. +44 (0) 20 7572 1187 or . Please use the following participant pin code: 95314096#

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Jeppe Ilkjær, tel. , mobile

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,300 people worldwide and is listed on Nasdaq Copenhagen. Find more information at .

Attachment

EN
09/08/2018

Underlying

ALK BALK-abello A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-abello A/S Class B

Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK165.00) - European tablet growth shifts gear

Last night, ahead of time, ALK-Abello published its Q1 results and increased its FY top-line guidance on much stronger than expected European tablet sales growth of c28% (consensus c15%). At the same time, the company announced a cost-cutting programme in connection with its ongoing strategic review, which should help it reach its c25% EBIT margin target by 2025. We reiterate our BUY and have raised our target price to DKK165 (145).

ALK B ALK-ABELLO A/S CLASS B
05/03/24 May 3, 2024 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK145.00) - Set for still-strong European tablet...

We expect another strong quarter for European tablet sales in Q1, up c15% YOY, marking a third consecutive quarter with growth in the teens, which should help boost investor confidence (results due at 07:00 CET on 3 May). However, due to tough comparables for the legacy business and seasonality patterns, we expect the 2024 guidance to be maintained. We reiterate our BUY and have raised our target price to DKK145 (140).

ALK B ALK-ABELLO A/S CLASS B
04/26/24 April 26, 2024 1 EN
Free Trial
ALK B ALK-abello A/S ...

Alk-Abello A S: 1 director

A director at Alk-Abello A S bought 1,880 shares at 132.600DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

ALK B ALK-ABELLO A/S CLASS B
03/07/24 March 7, 2024 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK140.00) - Q3 rebound was not a one-off

While the Q4 results were fairly in line, sales growth for the important European tablets was stronger than expected, showing the rebound in Q3 was not a one-off. In addition, the 2024 guidance notably suggests organic growth returning to >10% and still-strong margin expansion, while the CMD in Q2 is likely to reconfirm the 2025 EBIT margin target. We reiterate our BUY and have raised our target price to DKK140 (127). European tablet momentum still strong. Q4 organic growth of c10% was largely ...

ALK B ALK-ABELLO A/S CLASS B
02/09/24 February 9, 2024 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK127.00) - Looking for continued tablet growth

We expect the focus of the Q4 results to be on ALK showing the rebound in European tablet growth in Q3 was not a one-off, which should further help restore investor confidence. We also expect it to provide guidance suggesting organic growth returning to >10% in 2024 and still-strong margin expansion. However, we believe it is still too early for a strategy update. We reiterate our BUY and have raised our target price to DKK127 (120).

ALK B ALK-ABELLO A/S CLASS B
02/02/24 February 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch